We are the Orphan Drug Specialists

Committed to the cause

The P4A family are a unified andpassionate team who truly careabout access for orphan drugs and ensuring optimal client outcomes.

Client supporting services

We design bespoke solutions tosupport each commercialization journey; from initial clinical stage development to full maturity.

Thought provoking insights

P4A’s knowledge of rare dieases is built on decades of experience. Discover how much we really know in our published output.

With P4A you are
getting the best

Since 2015 we have been proud to partner and support clients who are at the forefront of creating groundbreaking new treatments and therapies.

A world class team brimming with
expertise, passion and talent.

We carefully select and recruit the highest calibre of personnel. Every member of
our team is an expert in their field and passionate about access for Rare Diseases.

Our core services

As global experts in access for orphan drug, cell and gene therapy,
we truly understand the complexity and challenges of the market
access environment. P4A solutions are designed to be bespoke
to your situation, location and needs. One size does not fit all.

Want to understand more about
what we do and how we do it?

Our 2-minute promotional video will give you a thorough overview
into P4A and our tailored, meticulous and innovative approach.


We are an award-winning global consultancy and recognised
for excellence in access for orphan drugs & Cell and Gene Therapies.

Find out what we’ve been up to


Calls for reform in the assessment of orphan drugs in Germany, upon the implementation of EU Joint Evaluation.

OD (orphan drug) privilege status under the AMNOG procedure means that ODs are currently exempt from providing comparative data for their assessment. They are assumed to have a positive added benefit (with the lowest rating possible being a positive but unquantifiable added benefit), even when the data is insufficient to support this. If sales over 12 months surpass the €30 million mark, this privilege is revoked, and a full assessment is performed based on comparative data. 

Read More